"Als größtes Universitätsklinikum im Norden deckt das UKSH mit 92 Kliniken und Instituten in Kiel und Lübeck das gesamte Spektrum der modernen Medizin ab. 500.000 Patientinnen und Patienten profitieren jedes Jahr von der engen Verknüpfung der Spitzenmedizin des UKSH mit der innovativen Forschung der Universitäten in Kiel und Lübeck. Forschungsergebnisse gelangen hier direkt in die medizinische Praxis. Das Ergebnis ist ein exzellentes klinisches Niveau: Das UKSH ist Garant für höchst individualisierte sowie interdisziplinäre Diagnostik und Therapie. Dazu zählen medizinische Innovationen wie die Präzisionsmedizin für chronische Entzündungserkrankungen und Krebserkrankungen ebenso wie die digitalen Medien."

During the past decade, Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I" #1 collaborator was "Celgene Corporation" with 1 trials as a collaborator and "ClinAssess GmbH" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I" are "Breast Cancer" (1 trials), "Carcinoma, Non-Squamous Non-Small Cell Lung" (1 trials), "Chronic Rhinosinusitis" (1 trials), "Cytomegalovirus Infections" (1 trials) and "Influenza" (1 trials). Many other conditions were trialed in "Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I" in a lesser frequency.

Most popular intervention types in "Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I" are "Drug" (6 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Baloxavir Marboxil" (1 trials), "Carboplatin" (1 trials) and "Docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I" are 5 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".